Target intelligence / Profile preview

PTEN-induced kinase 1 and Parkin pathway (PINK1/Parkin pathway)

Target
PINK1/Parkin pathway
Molecular classification
Enzyme (PINK1 is a serine/threonine-protein kinase; Parkin is an E3 ubiquitin ligase), Signal transduction complex, Other (Mitochondrial quality control machinery)
01

Overview

The PINK1/Parkin pathway refers to the coordinated action between PTEN-induced kinase 1 (PINK1)—a mitochondrial serine/threonine-protein kinase—and Parkin, an E3 ubiquitin ligase. This signaling axis plays a central role in maintaining mitochondrial integrity through selective autophagic removal ("mitophagy") of damaged mitochondria. Under normal conditions, PINK1 is imported into healthy mitochondria where it is rapidly degraded. When mitochondria become depolarized or dysfunctional, PINK1 accumulates on the outer membrane where it becomes activated through autophosphorylation. Activated PINK1 then phosphorylates both ubiquitin molecules on the outer membrane proteins and the Ubl domain of cytosolic Parkin, triggering conformational changes that recruit and activate Parkin at the site. Once recruited, active Parkin ubiquitylates numerous outer mitochondrial membrane proteins with various types of polyubiquitin chains—a process that flags these organelles for recognition by autophagic machinery leading to their degradation within lysosomes. This mechanism serves as a critical quality-control process protecting neurons from stress-induced cell death due to accumulation of defective mitochondria. Mutations in either PINK1 or Park2 (Parkin) genes cause autosomal recessive early-onset Parkinson’s disease due to failure in this protective mitophagy mechanism. The search for small-molecule activators has identified compounds such as kinetin riboside derivatives and niclosamide as potential pharmacological tools but no approved therapies exist yet targeting this axis directly. In summary, the PINK1/Parkin pathway represents an essential enzymatic signaling cascade regulating neuronal health via targeted clearance of dysfunctional mitochondria—a validated therapeutic target especially relevant in neurodegenerative diseases like Parkinson's disease.

Other names
PINK1-Parkin pathwayPTEN-induced putative kinase 1 and Parkin pathwayMitochondrial quality control pathway (context-dependent)
02

Mechanism of action

Activation of mitophagy via phosphorylation of ubiquitin and Parkin by PINK1, leading to recruitment of Parkin to depolarized mitochondria for ubiquitylation and subsequent autophagic degradation.

03

Biological functions

Mitochondrial quality controlMitophagy (autophagic removal of damaged mitochondria)Regulation of mitochondrial morphology, fission, and fusionCell survival under stress conditions
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease)Cancer (mutations in both genes have been linked to some cancers)
05

Safety considerations

Therapeutic challenges include specificity—activating mitophagy systemically could affect healthy cells or tissues. Long-term effects on mitochondrial dynamics are not fully understood. Off-target mitochondrial damage by candidate drugs is a concern.
06

Interacting drugs

Kinetin riboside and its prodrugs ("ProTides")

1 more in the full profile.

07

Biomarkers

No widely established clinical biomarkers specific for this pathway. However, phosphorylated ubiquitin at Ser65 or phosphorylated Parkin may serve as research biomarkers for activation status in cellular models.

Beyond the preview

Go deeper on PTEN-induced kinase 1 and Parkin pathway (PINK1/Parkin pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTEN-induced kinase 1 and Parkin pathway (PINK1/Parkin pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call